Cargando…

Effects of Atomoxetine for the Treatment of Neurogenic Orthostatic Hypotension in Patients With Alpha-synucleinopathies: A Systematic Review of Randomized Controlled Trials and a Focus-Group Discussion

BACKGROUND AND PURPOSE: Neurogenic orthostatic hypotension (nOH) is one of the most important nonmotor symptoms in patients with α-synucleinopathies. Atomoxetine is a selective norepinephrine transporter blocker that is a treatment option for nOH. This systematic review and expert focus-group study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Yu Jin, Kim, Aryun, Okamoto, Luis E., Hong, Woi-Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Neurological Association 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982187/ https://www.ncbi.nlm.nih.gov/pubmed/36647224 http://dx.doi.org/10.3988/jcn.2022.0018

Ejemplares similares

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
por: Byun, Jung‐Ick, et al.
Publicado: (2019)

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
Publicado: (2020)

Neurogenic orthostatic hypotension: the very basics
por: Kaufmann, Horacio, et al.
Publicado: (2017)

Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management
por: Metzler, Manuela, et al.
Publicado: (2012)

Neurogenic orthostatic hypotension – management update and role of droxidopa
por: Vijayan, Joy, et al.
Publicado: (2015)

Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
por: François, Clément, et al.
Publicado: (2019)

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
por: Biaggioni, Italo, et al.
Publicado: (2017)

Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies
por: Kalra, Dinesh K, et al.
Publicado: (2020)

Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
por: Cutsforth-Gregory, Jeremy K., et al.
Publicado: (2019)

Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
por: Eisenhofer, Graeme, et al.
Publicado: (2021)

Reduction in Pulse Pressure during Standing Can Distinguish Neurogenic Orthostatic Hypotension
por: Jung, Kyu-On, et al.
Publicado: (2021)

Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson's Disease
por: McCullough, Peter A.
Publicado: (2019)

Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms
por: Eschlböck, Sabine, et al.
Publicado: (2017)

Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension
por: Raj, Satish R, et al.
Publicado: (2019)

Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa
por: Biaggioni, Italo, et al.
Publicado: (2015)

Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Goodman, Brent P., et al.
Publicado: (2017)

Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
por: Kaufmann, Horacio
Publicado: (2017)

Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Claassen, Daniel, et al.
Publicado: (2017)

Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension
por: Isaacson, Stuart H., et al.
Publicado: (2021)

The effects of caffeine in adults with neurogenic orthostatic hypotension: a systematic review
por: Gibbon, Jake Ryan, et al.
Publicado: (2021)

Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach
por: Amjad, Fahd, et al.
Publicado: (2021)

Neurogenic Orthostatic Hypotension: a Common Complication of Successful Pancreas Transplantation
por: Kuten, Samantha A., et al.
Publicado: (2021)

Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review
por: Hoxhaj, Pranvera, et al.
Publicado: (2023)

Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial
por: Kaufmann, Horacio, et al.
Publicado: (2014)

Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa
por: Isaacson, Stuart H, et al.
Publicado: (2014)

Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
por: François, Clément, et al.
Publicado: (2016)

Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Lew, Mark, et al.
Publicado: (2017)

Neglected cause of recurrent syncope: a case report of neurogenic orthostatic hypotension
por: Miller, Robert J H, et al.
Publicado: (2019)

Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
por: Hauser, Robert A., et al.
Publicado: (2016)

Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers
por: Claassen, Daniel O., et al.
Publicado: (2018)

Utility of autonomic testing for the efficient diagnosis and effective pharmacological management of neurogenic orthostatic hypotension
por: Alam, Sami bin, et al.
Publicado: (2019)

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease
por: Kremens, Daniel, et al.
Publicado: (2017)

2198 Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension
por: McDonell, Katherine, et al.
Publicado: (2018)

Management of Neurogenic Orthostatic Hypotension in Neurodegenerative Disorders: A Collaboration Between Cardiology and Neurology
por: Amjad, Fahd S., et al.
Publicado: (2021)

Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial
por: Kaufmann, Horacio, et al.
Publicado: (2021)

Neurogenic orthostatic hypotension with Parkinson's disease as a cause of syncope: A case report
por: Li, Ya, et al.
Publicado: (2021)

Early-onset hereditary isolated non-neurogenic orthostatic hypotension in a Swedish family
por: Fagius, Jan, et al.
Publicado: (2023)

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy
por: Goodman, Brent P., et al.
Publicado: (2017)

Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension
por: Mehdirad, Ali, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sq8grfl9236hg6gqggiqhg2h8d